InsiderTrades.com logo
44-year Wall Street Vet: “Permanent devastation is coming to America”
From InvestorPlace   |   Ad
After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.
The information in this video is crucially valuable.

Michael Benkowitz Biography and Net Worth

COO of United Therapeutics
  • LinkedIn
  • Phone
  • Email
  • Website


Mr. Benkowitz joined United Therapeutics in 2011 as our Executive Vice President, Organizational Development, and was promoted to President and Chief Operating Officer in 2016.

He is responsible for all of our commercial, medical affairs, and corporate compliance activities, most company-wide administrative functions, including human resources and information technology, many of our business development efforts, and several of our key business alliances and partnerships.

What is Michael Benkowitz's net worth?

The estimated net worth of Michael Benkowitz is at least $873,912.24 as of August 7th, 2024. Mr. Benkowitz owns 2,577 shares of United Therapeutics stock worth more than $873,912 as of September 14th. This net worth approximation does not reflect any other investments that Mr. Benkowitz may own. Additionally, Mr. Benkowitz receives a salary of $2,830,000.00 as COO at United Therapeutics. Learn More about Michael Benkowitz's net worth.

How old is Michael Benkowitz?

Mr. Benkowitz is currently 52 years old. There are 4 older executives and no younger executives at United Therapeutics. The oldest executive at United Therapeutics is Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D., Founder, Chairman & CEO, who is 69 years old. Learn More on Michael Benkowitz's age.

What is Michael Benkowitz's salary?

As the COO of United Therapeutics Co., Mr. Benkowitz earns $2,830,000.00 per year. The highest earning executive at United Therapeutics is Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D., Founder, Chairman & CEO, who commands a salary of $5,320,000.00 per year. Learn More on Michael Benkowitz's salary.

How do I contact Michael Benkowitz?

The corporate mailing address for Mr. Benkowitz and other United Therapeutics executives is 1040 SPRING ST, SILVER SPRING MD, 20910. United Therapeutics can also be reached via phone at (301) 608-9292 and via email at [email protected]. Learn More on Michael Benkowitz's contact information.

Has Michael Benkowitz been buying or selling shares of United Therapeutics?

During the last quarter, Michael Benkowitz has sold $8,084,500.00 in United Therapeutics stock. Most recently, Michael Benkowitz sold 25,000 shares of the business's stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $323.38, for a transaction totalling $8,084,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $833,350.26. Learn More on Michael Benkowitz's trading history.

Who are United Therapeutics' active insiders?

United Therapeutics' insider roster includes Michael Benkowitz (COO), Christopher Causey (Director), Raymond Dwek (Director), James Edgemond (CFO), Paul Mahon (EVP), Nilda Mesa (Director), Judy Olian (Director), Christopher Patusky (Director), Martine Rothblatt (CEO), and Louis Sullivan (Director). Learn More on United Therapeutics' active insiders.

Are insiders buying or selling shares of United Therapeutics?

During the last twelve months, insiders at the biotechnology company sold shares 71 times. They sold a total of 360,535 shares worth more than $96,995,115.74. The most recent insider tranaction occured on September, 9th when CFO James Edgemond sold 7,802 shares worth more than $2,694,888.82. Insiders at United Therapeutics own 12.5% of the company. Learn More about insider trades at United Therapeutics.

Information on this page was last updated on 9/9/2024.

Michael Benkowitz Insider Trading History at United Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/7/2024Sell25,000$323.38$8,084,500.002,577View SEC Filing Icon  
See Full Table

Michael Benkowitz Buying and Selling Activity at United Therapeutics

This chart shows Michael Benkowitz's buying and selling at United Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

United Therapeutics Company Overview

United Therapeutics logo
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Read More

Today's Range

Now: $339.12
Low: $337.52
High: $347.29

50 Day Range

MA: $336.73
Low: $313.29
High: $363.55

2 Week Range

Now: $339.12
Low: $208.62
High: $366.08

Volume

455,672 shs

Average Volume

489,321 shs

Market Capitalization

$15.09 billion

P/E Ratio

16.03

Dividend Yield

N/A

Beta

0.57
44-year Wall Street Vet: “Permanent devastation is coming to America”
From InvestorPlace   |   Ad
After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.
The information in this video is crucially valuable.